# Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric

> **NCT06181695** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 182 (estimated)

## Conditions studied

- Vaso-occlusive Crisis

## Interventions

- **DRUG:** Sufentanil

## Key facts

- **NCT ID:** NCT06181695
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-02
- **Primary completion:** 2026-05-30
- **Final completion:** 2027-05-29
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06181695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06181695, "Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06181695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*